{"id":28777,"date":"2016-11-15T18:02:35","date_gmt":"2016-11-15T17:02:35","guid":{"rendered":"http:\/\/www.fedaiisf.it\/?p=28777"},"modified":"2016-11-16T11:54:36","modified_gmt":"2016-11-16T10:54:36","slug":"novartis-sale-al-terzo-posto-dellaccess-to-medicine-index","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/novartis-sale-al-terzo-posto-dellaccess-to-medicine-index\/","title":{"rendered":"Novartis rises to third place in the Access to Medicine Index"},"content":{"rendered":"<p><img loading=\"lazy\" decoding=\"async\" class=\"alignleft\" src=\"https:\/\/accesstomedicinefoundation.org\/media\/atmf\/ATMFcover.jpg\" alt=\"Risultati immagini per Access to Medicine Index 2016\" width=\"216\" height=\"305\" \/>Novartis earns third place in the 2016 Access to Medicine Index ranking (in 2014 it was in 4th position) which measures every two years the performance achieved by the top 20 pharmaceutical companies in improving access to medicines and healthcare in countries where developing. The assessment takes into account seven metrics, including drug access management, resource capacity development, pricing, manufacturing and distribution.<\/p>\n<p>\u201cNovartis,\u201d said Joseph Jimenez, CEO of Novartis. shares the main objective of the Access to Medicine Index: to bridge the gap that penalizes access to medicines by developing countries. We are pleased that our activities have been recognised, but more needs to be done. To further improve access, we will continue to work on creating more scalable and sustainable approaches to improve the affordability and availability of medicines for patients in the most deprived conditions.&quot;<\/p>\n<p>Novartis&#039; efforts were recognized for two programs, in particular: Novartis Access, the portfolio of 15 covered and off-patent medicines to fight chronic diseases in low-income countries and ComHIP, a program supported by the Novartis Foundation and its partners to evaluate the impact of an innovative health care model for the control and self-management of hypertension in Ghana (Africa).<\/p>\n<p><a href=\"http:\/\/www.healthdesk.it\/cronache\/novartis-sale-terzo-posto-access-medicine-index\" target=\"_blank\" rel=\"noopener\"><span style=\"color: #0000ff;\"><em><time datetime=\"2016-11-15T13:21:12+0100\">November 15, 2016 \u2013 HealthDesk<\/time><\/em><\/span><\/a><\/p>\n<p>Related news: <a href=\"http:\/\/accesstomedicineindex.org\/media\/atmi\/Access-to-Medicine-Index-2016.pdf\" target=\"_blank\" rel=\"noopener\"><span style=\"color: #0000ff;\">Access to Medicine Index 2016<\/span><\/a><\/p>\n<p><a href=\"http:\/\/www.affaritaliani.it\/cronache\/accesso-ai-farmaci-johnson--johnson-secondo-al-mondo-450338.html\" target=\"_blank\" rel=\"noopener\"><span style=\"color: #0000ff;\">Access to medicines, Johnson &amp; Johnson second in the world<\/span><\/a><\/p>\n<p><a href=\"http:\/\/www.healthdesk.it\/cronache\/gsk-vertice-access-medicine-index\" target=\"_blank\" rel=\"noopener\"><span style=\"color: #0000ff;\">Gsk at the top of the Access to Medicine Index<\/span><\/a><\/p>\n<p><img decoding=\"async\" class=\"aligncenter\" src=\"http:\/\/blogs-images.forbes.com\/judystone\/files\/2016\/11\/Access-to-Medicine-Index-2016_overall-ranking-e1479127123316.jpg?width=960\" alt=\"Risultati immagini per Access to Medicine Index 2016\" \/><\/p>","protected":false},"excerpt":{"rendered":"<p>Novartis guadagna il terzo posto nella classifica 2016 dell\u2019Access to Medicine Index (nel 2014 era in 4a posizione) che misura ogni due anni le performance ottenute dalle prime 20 aziende farmaceutiche nel migliorare l\u2019accesso ai farmaci e all\u2019assistenza sanitaria nei Paesi in via di sviluppo.\u00a0 La valutazione tiene conto di sette parametri, tra cui la &hellip;<\/p>","protected":false},"author":4,"featured_media":28780,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[47,29],"class_list":["post-28777","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizie","tag-big-pharma","tag-prezzo-farmaci"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/28777","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=28777"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/28777\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/28780"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=28777"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=28777"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=28777"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}